Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Update June 2022

Rothschedl, E. and Wolf, S. (2022): Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Update June 2022. Oncology Fact Sheet Nr. 85.

[thumbnail of Oncology Fact Sheet Nr.85_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
112kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 400-600 Ureter. Bladder. Urethra
Language:	English
Series Name:	Oncology Fact Sheet Nr. 85
Deposited on:	28 Mar 2022 12:50
Last Modified:	10 Jul 2025 11:33

Repository Staff Only: item control page